Results 41 to 50 of about 44,322 (189)
The cardiomyopathies are a heterogeneous collection of heart muscle disorders with diverse genetic and non-genetic aetiologies. The advent of molecular genetics and next-generation sequencing has transformed understanding of the mechanisms of disease ...
Yavari, Arash +7 more
core +2 more sources
A green tea extract catechin EGCg: Therapeutic potential for pediatric cardiomyopathies
Cardiomyopathies comprise a group of disorders wherein the primary defect is in cardiac myocytes. The common forms of pediatric cardiomyopathies, classified according to their morphological and functional manifestations, include dilated cardiomyopathy ...
Junjun Quan +4 more
doaj +1 more source
MitraClip (Abbott Laboratories, Abbott Park, IL) is validated in high-risk patients with severe degenerative mitral regurgitation (MR); however, it is not well established for functional MR in hypertrophic cardiomyopathy (HCM).
Catherine Bourque, MD +8 more
doaj +1 more source
Cardiomyocyte Dysfunction in Inherited Cardiomyopathies
Inherited cardiomyopathies form a heterogenous group of disorders that affect the structure and function of the heart. Defects in the genes encoding sarcomeric proteins are associated with various perturbations that induce contractile dysfunction and ...
Nazha Hamdani +3 more
core +2 more sources
A very rare cause of pre‐capillary pulmonary hypertension: The PAMI syndrome
We report the first known case of PAMI syndrome associated with pulmonary arterial hypertension (PAH) with a positive response to cyclophosphamide and pulmonary vasodilators. The patient's history began at 7 months with severe pancytopenia and fever.
Manuela Iseppi +5 more
doaj +1 more source
Human-induced pluripotent stem cells in modeling inherited cardiomyopathies
Our current understanding of molecular mechanisms of cardiomyopathies has been elucidated from genetic animal models. Induced pluripotent stem cells (iPSCs) can provide a platform to improve our understanding of familial cardiomyopathies diseases.
Subhoshree Ghose +3 more
doaj +1 more source
Background: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr +7 more
doaj +1 more source
Pediatric cardiomyopathies are rare diseases with an annual incidence of 1.1 to 1.5 per 100 000. Dilated and hypertrophic cardiomyopathies are the most common; restrictive, noncompaction, and mixed cardiomyopathies occur infrequently; and arrhythmogenic ...
Thrush, Philip T +37 more
core +1 more source
Diagnosis of cardiomyopathies: tips and tricks for internists and general practitioners
Cardiomyopathies are little known to internists and general practitioners (GPs), and not always able to arouse the interest of cardiologists. Probably, this happens because cardiomyopathies are perceived as rare and complex disorders, a prerogative of a ...
Giuseppe Palmiero +2 more
doaj +1 more source

